

Hypersomnia Market Outlook 2025-2035 | Epidemiology, Drugs Sales, Pipeline Therapies, and Regional Outlook

The report provides a detailed analysis of the current hypersomnia marketed drugs and late-stage pipeline drugs.

BROOKLYN, NY, UNITED STATES, July 11, 2025 /EINPresswire.com/ --

According to the latest report by IMARC Group, the hypersomnia markets are expected to exhibit a CAGR of 6.47% during 2025-2035. Hypersomnia is a sleep disorder which manifests itself through symptoms such as excessive daytime sleepiness. It is considered a rising matter of public health. This disorder could immensely hinder an individual's ability to enjoy her/his life working, studying, or fulfilling social engagements. The hypersomnia market is witnessing dramatic changes in implementation and research, and awareness; treatments are following suit by 2025.



Hypersomnia Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035

Increasing general and professional awareness of sleep disorders is the most prominent trend observed in the hypersomnia market. In the past few years, a huge effort has been made to educate people about hypersomnia symptoms and repercussions. The buoyancy from this awareness has got more patients seeking medical care, though diagnostics have become rather common. As patient diagnoses increase, there will be an increasing demand for treatment options; this demand will indeed tilt the landscape of the market big time.

Apart from heightened awareness, the hypersomnia market is also being driven by advancements in diagnostic technologies. Sleep studies and polysomnography are now more widely available and advanced, allowing for proper diagnoses of hypersomnia and other sleep disorders. The improvements in technology make it possible for healthcare professionals to distinguish between the different hypersomnia types, including idiopathic hypersomnia and narcolepsy, enabling them to provide more directed and effective treatment regimens. As

diagnostic methods continue to evolve, the market is likely to see a rise in patient referrals and treatment initiations.

The development of new therapeutics is another key trend shaping the hypersomnia market. Traditional treatments, such as stimulants and wakefulness-promoting agents, have been the mainstay for managing hypersomnia symptoms. But new studies have prompted the investigation of new therapies, such as drugs that act specifically on neurochemical pathways associated with sleep. These new treatments have the goal of controlling symptoms more effectively with fewer unwanted effects, which is a winning combination for patients and physicians alike.

Furthermore, the increasing incidence of mental illnesses like depression and anxiety is driving the market for hypersomnia. Hypersomnia is often seen as a secondary symptom of these disorders, resulting in a greater demand for holistic treatment solutions addressing both sleep disorders and mental illness. With the stigma around mental illness slowly fading, more and more patients are requesting combined care solutions, again pushing the hypersomnia market.

Technological innovations are also impacting how hypersomnia is treated. The development of telemedicine and digital health platforms has allowed for greater ease of access for patients to receive treatment and ongoing care. Virtual appointments and remote monitoring platforms allow healthcare professionals to monitor progress and make changes to treatment plans as appropriate. This movement towards digital health solutions not only enhances patient engagement but also the overall management of hypersomnia, making it a prominent market trend.

Finally, the shift towards personalized medicine is likely to have a profound effect on the hypersomnia market by 2025. Individualized treatment plans customized according to a patient's specific genetic, biochemical, and lifestyle determinants are becoming increasingly possible. Personalized treatment can result in more effective treatment outcomes and enhanced patient satisfaction as therapies are customized to address the specific needs of each patient.

Request to get a PDF Sample Report: <https://www.imarcgroup.com/hypersomnia-market/requestsamplereport>

Key Highlights:

Hypersomnia, or excessive daytime sleepiness, affects four to six percent of the general population.

Hypersomnia is most common in adolescents, and it is uncommon in those beyond the age of 30.

In pediatric clinics, middle school-aged children are twice as likely as preschool-aged children to

have excessive daytime sleepiness.

Men are more likely than women to suffer from hypersomnia, which may be caused by sleep apnea syndromes.

In elderly people, patient-reported hypersomnia is connected with cognitive and functional deficits.

This report also provides a detailed analysis of the current hypersomnia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Buy the full Hypersomnia Market Epidemiology Report with TOC:

<https://www.imarcgroup.com/checkout?id=9215&method=809>

Competitive Landscape With Key Players:

The competitive landscape of the hypersomnia market has been studied in the report with the detailed profiles of the key players operating in the market.

Jazz Pharmaceuticals, Inc.

Takeda Pharmaceutical Company Limited

Alkermes

Centessa Pharmaceuticals

Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

7 Major Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

Myelodysplastic Syndrome Market Epidemiology Report 2025-2035:

<https://www.einpresswire.com/article/828383752/myelodysplastic-syndrome-market-epidemiology-report-2025-2035-pipeline-therapies-drugs-sales-and-regional-outlook>

Keloid Market Epidemiology Report 2025-2035:

<https://www.einpresswire.com/article/828355193/keloid-market-epidemiology-report-2025-2035-pipeline-therapies-drug-sales-and-regional-outlook>

Gestational Diabetes Market Epidemiology Report 2025-2035:

<https://www.einpresswire.com/article/828346890/gestational-diabetes-market-outlook-2025-2035-epidemiology-drugs-sales-pipeline-therapies-and-regional-outlook>

Hair Diseases Market Epidemiology Report 2025-2035:

<https://www.einpresswire.com/article/828331227/hair-diseases-market-size-to-reach-usd-13-0-billion-by-2035-epidemiology-report-by-imarc-group>

Dyspnea Market Epidemiology Report 2025-2035:

<https://www.einpresswire.com/article/828301634/dyspnea-market-size-to-reach-usd-11-827-3-million-by-2035-epidemiology-report-by-imarc-group>

Elena Anderson

[email us here](#)

IMARC Services Private Limited

+1 631-791-1145

This press release can be viewed online at: <https://www.einpresswire.com/article/830426640>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.